Collecting health data is now easier than ever before. There has been an increase in the advancements made in pharma over the past few years. With more implementation of AI together with machine learning technologies, the capabilities of pharma have been enhanced in various areas. These include clinical trials, drug discovery, predictive forecasting, and the identification of diseases.
The COVID-19 pandemic that ravaged the whole world and the entrance of key players in the medical industry have impacted pharma. They have brought the pressure to improve in terms of both accelerating their procedures as well as making more affordable drugs available on the market.
The availability of massive volumes of health data is among the factors that have sparked the developments being experienced in pharma. There has been more access to health data much faster and securely. This is made possible by the new technologies and solutions that are continuously being developed. For instance, pharma has access to real-time health data, both genomic and clinical, through EMRs and EHRs.
Remote access to a patient’s health data in real time has now been made possible by the new gadgets being developed. Companies and organisations are now able to access data from shared pools through shared initiatives without necessarily exchanging their trade secrets. With the new technologies that continue to avail various forms of health data, more advancements are expected in pharma. These changes include speeding up the processes that would ordinarily take a lot of time as well as making them smarter and cheaper.
Ways in which pharma obtains health data in order to improve efficiency:
In the discovery and development of drugs, information on the real-time health data of various populations enhances a better understanding of the medication needs of people pharma. They are then able to produce drugs that cater to these needs.
In clinical trials, virtual clinical trials and some trials being done remotely by pharma have been made possible by access to health data. This has therefore sped up the processes involved in the recruitment and retention of patients as well as mitigating the challenges involved. For instance, pharma is able to recruit subjects from various locations, including from remote areas, regardless of their demographics, thus overcoming the challenge of geographic obstacles.
In pharmacovigilance, pharma is able to monitor the vital signs of patients before and after the release of drugs into the market through remote monitoring of vital signs. This is made possible through the integration of technologies in the remote monitoring of vital signs. This, therefore, enables pharma to have access to real-time health data regularly. This enables them to track the reactions of the patients after consuming medication in order to ensure that the drugs are safe and effective.
In sales and marketing, pharma improves sales and marketing by using the real-time health data they collect remotely to learn the needs of the patients and offer them affordable and easily accessible drugs. Remote monitoring of vital signs can be integrated into Pharma’s apps from which patients can track their health status. They can also offer drug suggestions and discounts on products beneficial to the health status of the patients.
In terms of adherence to medication, pharma companies can use real-time health data to identify the behaviors and patterns of patients. This is particularly true in matters of adherence rates to prescriptions of medications. This way, they understand what affects adherence to prescriptions and are able to offer ways to improve. They are also able to engage with patients located in remote areas and encourage the completion of treatments.
